Oncolytics Biotech Inc. Announces Addition to Senior Management
Team
CALGARY, Nov. 12, 2012 /PRNewswire/ - Oncolytics Biotech
Inc. ("Oncolytics" or the "Company") (TSX:ONC, NASDAQ:ONCY) today
announced the appointment of Mr. Kirk
Look to the role of Chief Financial Officer.
Mr. Look has served as Oncolytics' Controller since
2003 and has been the Chief Financial Officer of Oncolytics Biotech
(U.S.) Inc. since 2009. Prior to joining Oncolytics, Mr. Look held
progressively senior audit roles with Ernst & Young LLP in both
North and South America over an
eight year period. He holds a Bachelor of Commerce degree from the
University of Calgary and is a
Chartered Accountant.
"I am very pleased to announce Mr. Look's
appointment as CFO," said Dr. Brad
Thompson, President and CEO of Oncolytics. "We are looking
forward to his contributions to the Company's ongoing development
in his new role."
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based
biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics. Oncolytics' clinical
program includes a variety of human trials using REOLYSIN, its
proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit:
www.oncolyticsbiotech.com.
This press release contains forward-looking
statements within the meaning of the U.S. Securities Act of 1933,
as amended, and U.S. Securities Exchange Act of 1934, as amended,
and forward-looking information within the meaning of Canadian
securities laws. Statements, other than statements of historical
facts, included in this press release that address activities,
events or developments that Oncolytics expects or anticipates will
or may occur in the future, including such things as the
appointment and performance of a new Chief Financial Officer, the
Company's belief as to the potential of REOLYSIN as a cancer
therapeutic, and other such matters are forward-looking
statements and forward-looking information and involve known and
unknown risks and uncertainties, which could cause the Company's
actual results to differ materially from those in the
forward-looking statements and forward-looking information. Such
risks and uncertainties include, among others, risks related to the
statistical sufficiency of patient enrollment numbers in separate
patient groups, the availability of funds and resources to pursue
research and development projects, the efficacy of REOLYSIN as a
cancer treatment, the tolerability of REOLYSIN outside a controlled
test, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize
REOLYSIN, uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory
process. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
the forward-looking statement and forward-looking information.
Investors are cautioned against placing undue reliance on
forward-looking statements and forward-looking information. The
Company does not undertake to update these forward-looking
statements and forward-looking information, except as required by
applicable laws.
SOURCE Oncolytics Biotech Inc.